Journal Article

Ovarian survival after pelvic radiation: transposition until the age of 35 years

Jansen, Frank W, de Kroon, Cornelis D, Knoester, Dan, Peters, Alexander A W, Hoekman, Ellen J, Carina G J M Hilders

2018

Overview

PurposeTo evaluate the effectiveness of ovarian transposition (OT) prior to radiationtherapy (RT) and to evaluate the effect of age on ovarian survival (OS) after OT.MethodsWe performed a retrospective control study, with women (aged < 45 years) who underwent OT prior to pelvic radiation, versus women diagnosed with cervical cancer and treated with hysterectomy/trachelectomy and radiation therapy. All women were treated between 1989 and 2010. The 5 years OS rate was calculated, with a sub-analysis for age (25–30; 31–35 and 36–40 years). Ovarian failure was defined as climacteric complaints (with or without starting hormone replacement therapy) and/or laboratory measurements (FSH > 40 IU/L and/or estradiol < 100 pmol/L), or bilateral salpingo oophorectomy. Women were censored at recurrence.ResultsTwenty-seven women after OT and 29 controls were included. The radiation dose was 44.8 Gy (25.0–63.0 Gy) and 46.3 Gy (45.0–50.0 Gy), respectively. The 5-year ovarian survival rate was 60.3% versus controls 0% (p < 0.001 95% CI 3.48–11.50). Despite the decrease in ovarian survival after OT with increasing age, in all age groups (25–30, 30–35 and 35–40) ovarian survival after OT was significantly better compared to women without OT (p = 0.001; p = 0.004 and p = 0.000, respectively). Neither intra-vaginal radiation therapy of concomitant chemotherapy in addition to pelvic radiation significantly altered ovarian survival.ConclusionsOur data shows that ovarian transposition prior to pelvic radiation is effective in women until the age of 35 years and needs to be discussed in patients aged 36–40 years.

• Publisher: Springer Nature B.V
• Subject: Age / Cervical cancer / Health risk assessment / Hormone replacement therapy / Radiation therapy